Acute Kidney Injury
Conditions
Keywords
Renal replacement therapy, Acute Kidney Injury, Furosemide Stress Test
Brief summary
The proposed study will evaluate if a standardised dose of furosemide administered in the 12 hours after RRT liberation can predict successful liberation in critically ill patients. The dose that will be administered is in accordance with the prescribing information.
Detailed description
Response to furosemide administration is commonly used in clinical practice to assess a patient's potential for RRT liberation. However, this administration is not standardized and practices varies greatly. Rapid recognition of unsuccessful RRT liberation is crucial to avoid further complications such as fluid overload or acid-base and electrolyte disorders. The FST corresponds to the intravenous administration of 1 mg/kg (1.5 mg/kg in previously exposed patients) of furosemide and the assessment of resulting diuresis in the following two hours. FST is able to predict progression from AKI stage I and II to stage III with a high sensitivity (87.1%) and specificity (84.1%), area under the ROC curve 0.87. However, the ability of FST to predict RRT liberation has never been formally assessed.
Interventions
The FST corresponds to the intravenous single-dose administration of 1 mg/kg (1.5 mg/kg in previously exposed patients) of furosemide and the assessment of resulting diuresis in the following two hours. In the 12 hours following the first RRT liberation, a FST will be performed. The test will be considered positive if urinary output is ≥200 mL in the two hours following furosemide administration.
Sponsors
Centre Hospitalier Universitaire Vaudois
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Receiving continuous or intermittent RRT for AKI * Having an indwelling urinary catheter * Clinical decision by physician in charge to attempt RRT liberation * lnformed consent signed by the patient himself / legal representative or authorization received from independent physician
Exclusion criteria
* Electrolyte disturbances or hemodynamic instability precluding the use of furosemide (sodium \> 155 mmol/L and/or potassium \< 3.0 mmol/L and/or metabolic alkalosis \> 7.50 and/or mean arterial pressure \< 60 mmHg) * Known furosemide allergy * Urine output ≥ 100 mL/h for at least two hours * Recent (\< 24 hours) FST * Known end-stage chronic renal disease at ICU admission * Withdrawal of life support decision taken before inclusion * Patient already participating in conflicting research study * Patient having already participated in this current study * Any other contraindication of furosemide
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Successful liberation of RRT within 72 hours after FST | within 72 hours | No renal replacement therapy administered |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Successful liberation of RRT at ICU discharge | At time of ICU discharge, assessed up to 90 days post inclusion | No renal replacement therapy administered |
| Successful liberation of RRT at hospital discharge | At time of hospital discharge, assessed up to 90 days post inclusion | No renal replacement therapy administered |
| Adverse events associated with the intervention | within 6 hours | (electrolyte disturbances, hypotension) |
Countries
Switzerland
Outcome results
None listed